Aantal gebruikers 2018-2022 voor ATC-subgroep A10BJ : Glucagonachtig peptide-1-agonisten (glp-1-agonisten)
- Raming voor de totale Zvw-populatie
| 2018 | 2019 | 2020 | 2021 | 2022 | |
|---|---|---|---|---|---|
| A10BJ01 Exenatide (Bydureon ®) | 870 | 746 | 585 | 477 | 410 |
| A10BJ02 Liraglutide (Victoza ®) | 11.561 | 11.700 | 9.895 | 8.328 | 16.657 |
| A10BJ03 Lixisenatide (Lyxumia ®) | 145 | 149 | 101 | 66 | 63 |
| A10BJ05 Dulaglutide (Trulicity ®) | 2.509 | 3.357 | 4.566 | 5.472 | 9.838 |
| A10BJ06 Semaglutide (Ozempic ®) | 1.264 | 12.095 | 26.156 | 42.219 | 62.381 |